1. Home
  2. PLSE vs AUPH Comparison

PLSE vs AUPH Comparison

Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$35.13

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.88

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
AUPH
Founded
2014
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
PLSE
AUPH
Price
$35.13
$14.88
Analyst Decision
Buy
Buy
Analyst Count
1
4
Target Price
$22.00
$17.25
AVG Volume (30 Days)
339.2K
1.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
$840.00
$17.54
Revenue Next Year
$287.54
$15.74
P/E Ratio
N/A
$60.02
Revenue Growth
N/A
20.38
52 Week Low
$12.56
$10.34
52 Week High
$36.79
$19.25

Technical Indicators

Market Signals
Indicator
PLSE
AUPH
Relative Strength Index (RSI) 68.96 37.04
Support Level $24.27 $14.60
Resistance Level N/A $15.23
Average True Range (ATR) 2.50 0.49
MACD 0.62 -0.10
Stochastic Oscillator 89.49 17.08

Price Performance

Historical Comparison
PLSE
AUPH

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: